Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like D*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
Daiichi Sankyo, Inc.	65597040601	Enhertu	2019-12-20	2295.9700	None	1	None	1	1	None	None	None	None	Average patient will need 4 vials each 3 week cycle. Estimated patient count forecasts are not made public.	None
Daiichi Sankyo, Inc.	65597040228	Turalio	2019-08-06	19800.0000	None	1	None	1	1	None	None	None	None	WAC based on monthly price assuming 400mg daily. As this is an oncology product, a "course of treatment may vary." The estimated patient population has not been made public. Turalio was developed by Daiichi Sankyo, Inc. There was no acquisition.	None
Daiichi Sankyo, Inc.	65597040220	Turalio	2019-08-06	19800.0000	None	1	None	1	1	None	None	None	None	WAC based on monthly price assuming 400mg daily. As this is an oncology product, a "course of treatment may vary." The estimated patient population has not been made public. Turalio was developed by Daiichi Sankyo, Inc. There was no acquisition.	None
Dr. Reddy's Laboratories, Inc.	43598041311	Daptomycin 500mg Powder for Injection	2019-05-06	445.0000	None	1	0	None	None	None	None	None	None	1) DRL does not estimate the number of patients for this drug. 2) Dr. Reddy’s did not acquire daptomycin.	https://oshpd.ca.gov/ml/v1/resources/document?rs:path=/Data-And-Reports/Documents/Topics/Cost-Transparency/Rx/Q2-New-Drug-Public-Release-Supporting-Documents/DRL-Drug-Price-Transparency-3-Day-Notice-Daptomycin-2019-06-21-14-Submission-ID-103939.pdf
Dr. Reddy's Laboratories, Inc.	43598069858	Carboprost Tromethamine 250mcg/1mL Solution for injection	2019-07-02	3189.9000	None	1	0	None	None	None	None	None	None	1) DRL does not estimate the number of patients for this drug. 2) Dr. Reddy’s did not acquire Carboprost. 3) Dr. Reddy’s Laboratories does not believe this information is publicly available and has not released this information in the public domain	None
Dr. Reddy's Laboratories, Inc.	43598069750	Vigabatrin for Oral Solution,USP 500 mg	2019-08-19	3652.9400	None	1	0	None	1	None	None	None	None	1) Dr. Reddy's does not estimate the number of patients for this drug. 2) Dr. Reddy’s did not acquire the product. 3) Dr. Reddy’s does not believe this information is publicly available and has not released this information in the public domain.	None
Dr. Reddy's Laboratories, Inc.	43598086560	Bortezomib for Injection 3.5mg/vial	2019-12-03	1602.9800	None	1	0	None	None	None	None	None	None	1) Dr. Reddy's Laboratories, Inc. does not estimate the number of patients for this drug. 2) Dr. Reddy’s Laboratories, Inc. did not acquire the product. 3) Dr. Reddy’s Laboratories, Inc. does not believe this information is publicly available and has not released this information in the public domain.	None
Dr. Reddy's Laboratories, Inc.	43598085330	Deferasirox Film coated tablets 90MG	2019-12-05	190.0300	None	1	1	None	None	None	None	None	None	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox FCT 90MG product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of 3 other approved AB-rated generics as well as the reference listed drug. Dr. Reddy’s Laboratories, Inc. did not acquire the product.This product has been in-licensed from the ANDA holder, MSN Labs, by Dr Reddy’s Laboratories, Inc. for the purpose of commercial marketing and distribution.	None
Dr. Reddy's Laboratories, Inc.	43598085130	Deferasirox Film coated tablets 360MG	2019-12-05	760.0800	None	1	1	None	None	None	None	None	None	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox FCT 360MG product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of 3 other approved AB-rated generics as well as the reference listed drug. Dr. Reddy’s Laboratories, Inc. did not acquire the product. This product has been in-licensed from the ANDA holder, MSN Labs, by Dr Reddy’s Laboratories, Inc. for the purpose of commercial marketing and distribution.	None
Dr. Reddy's Laboratories, Inc.	43598085530	Deferasirox Tablets for Oral Suspension 125MG	2019-12-05	190.0300	None	1	1	None	None	None	None	None	None	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox TFOS product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of 5 other approved AB-rated generics as well as the reference listed drug. Dr. Reddy’s Laboratories, Inc. did not acquire the product. This product has been in-licensed from the ANDA holder, MSN Labs, by Dr Reddy’s Laboratories, Inc. for the purpose of commercial marketing and distribution.	None
Dr. Reddy's Laboratories, Inc.	43598085630	Deferasirox Tablets for Oral Suspension 250MG	2019-12-05	380.0500	None	1	1	None	None	None	None	None	None	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox TFOS product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of 5 other approved AB-rated generics as well as the reference listed drug. Dr. Reddy’s Laboratories, Inc. did not acquire the product. This product has been in-licensed from the ANDA holder, MSN Labs, by Dr Reddy’s Laboratories, Inc. for the purpose of commercial marketing and distribution.	None
Dr. Reddy's Laboratories, Inc.	43598085430	Deferasirox Tablets for Oral Suspension 500MG	2019-12-05	760.0800	None	1	1	None	None	None	None	None	None	Dr. Reddy’s does not track the estimated number of patients to be prescribed a drug on a monthly basis. Specifically, Dr. Reddy’s lacks sufficient information to determine the total number of patients who may be prescribed its Deferasirox TFOS product given, among other things, (i) the unknown size of the prospective patient population meeting the relevant criteria; and (ii) the current existence of 5 other approved AB-rated generics as well as the reference listed drug. Dr. Reddy’s Laboratories, Inc. did not acquire the product. This product has been in-licensed from the ANDA holder, MSN Labs, by Dr Reddy’s Laboratories, Inc. for the purpose of commercial marketing and distribution.	None